 | Up a level |
Sommerer, Claudia; Duerr, Michael; Witzke, Oliver; Lehner, Frank; Arns, Wolfgang; Kliem, Volker; Ackermann, Daniel; Guba, Markus; Jacobi, Johannes; Hauser, Ingeborg A; Stahl, Rolf; Reinke, Petra; Rath, Thomas; Veit, Justyna; Mehrabi, Arianeb; Porstner, Martina; Budde, Klemens (2018). Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy. American journal of transplantation, 18(12), pp. 2965-2976. Wiley-Blackwell 10.1111/ajt.14897
Budde, Klemens; Becker, Thomas; Arns, Wolfgang; Sommerer, Claudia; Reinke, Petra; Eisenberger, Ute; Kramer, Stefan; Fischer, Wolfgang; Gschaidmeier, Harald; Pietruck, Frank; ZEUS Study Investigators, (2011). Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet, 377(9768), pp. 837-47. London: Elsevier 10.1016/S0140-6736(10)62318-5
Fangmann, Josef; Arns, Wolfgang; Marti, Hans-Peter; Hauss, Johann; Ketteler, Markus; Beckurts, Tobias; Boesmueller, Claudia; Pohanka, Erich; Martin, Pierre-Yves; Gerhardt, Moritz; Farese, Stefan; Neumayer, Hans-H; Floege, Juergen; Gurr, Caroline; Budde, Klemens; DACH Study Group, (2010). Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. Nephrology, dialysis, transplantation, 25(1), pp. 283-92. Oxford: Oxford University Press 10.1093/ndt/gfp468
